Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU

被引：1

作者：

Jose Casanova, Maria ^{[1
,2
]}

Caballol, Berta ^{[3
,4
]}

Jose Garcia, Maria ^{[5
,6
]}

Mesonero, Francisco ^{[7
]}

Rubin de Celix, Cristina ^{[1
,2
]}

Suarez-Alvarez, Patricia ^{[8
]}

Ferreiro-Iglesias, Rocio ^{[9
,10
]}

Martin-Rodriguez, Maria del Mar ^{[11
]}

de Francisco, Ruth ^{[12
,13
]}

Varela-Trastoy, Pilar ^{[14
]}

Bastida, Guillermo ^{[15
,16
]}

Carrillo-Palau, Marta ^{[17
]}

Nunez-Ortiz, Andrea ^{[18
]}

Ramirez-de la Piscina, Patricia ^{[19
]}

Ceballos, Daniel ^{[20
]}

Hervias-Cruz, Daniel ^{[21
]}

Munoz-Perez, Roser ^{[22
,23
]}

Velayos, Benito ^{[24
]}

Bermejo, Fernando ^{[25
,26
]}

Busquets, David ^{[27
]}

Cabacino, Manuel ^{[28
]}

Camo-Monterde, Patricia ^{[29
]}

Marin-Jimenez, Ignacio ^{[30
,31
]}

Munoz, Carmen ^{[32
]}

de la Pena-Negro, Luisa Carmen ^{[33
]}

Sierra-Moros, Eva ^{[34
]}

Barrio, Jesus ^{[35
]}

Brunet-Mas, Eduard ^{[36
,37
]}

Bujanda, Luis ^{[38
,39
]}

Canete, Fiorella ^{[40
,41
]}

Gomollon, Fernando ^{[42
,43
]}

Mancenido-Marcos, Noemi ^{[44
]}

Rodriguez-Lago, Iago ^{[45
]}

Rodriguez-Grau, Maria Carmen ^{[46
]}

Sicilia, Beatriz ^{[47
]}

Torra-Alsina, Sandra ^{[48
]}

Arranz-Hernandez, Laura ^{[49
]}

Carpio, Daniel ^{[50
]}

Garcia-Sepulcre, Mariana Fe A. ^{[51
]}

Gonzalez-Munoza, Carlos ^{[52
]}

Maria Huguet, Jose ^{[53
]}

Marquez-Mosquera, Lucia ^{[54
,55
]}

Lopez-Serrano, Maria Pilar ^{[56
]}

Ponferrada-Diaz, Angel ^{[57
]}

Chaparro, Maria ^{[1
,2
]}

Gisbert, Javier P. ^{[1
,2
]}

机构：

[1] Univ Autonoma Madrid UAM, Inst Invest Sanitaria Princesa IIS Princesa, Hosp Univ La Princesa, Dept Gastroenterol, Madrid, Spain

[2] CIBEREHD, Madrid, Spain

[3] IDIBAPS, Hosp Clin & Prov, Dept Gastroenterol, Barcelona, Spain

[4] CIBEREHD, Barcelona, Spain

[5] Hosp Univ Marques Valdecilla, Dept Gastroenterol, Santander, Spain

[6] IDIVAL, Santander, Spain

[7] Hosp Univ Ramon y Cajal, Dept Gastroenterol, Madrid, Spain

[8] Complejo Asistencial Univ Leon, Dept Gastroenterol, Leon, Spain

[9] Hosp Clin Univ Santiago de Compostela, Dept Gastroenterol, Santiago De Compostela, Spain

[10] Inst Invest Sanitaria Santiago de Compostela IDIS, Santiago De Compostela, Spain

[11] Hosp Univ Virgen de las Nieves, Dept Gastroenterol, Granada, Spain

[12] Hosp Univ Cent Asturias, Dept Gastroenterol, Oviedo, Spain

[13] ISPA, Oviedo, Spain

[14] Hosp Univ Cabuenes, Dept Gastroenterol, Gijon, Spain

[15] Hosp Univ & Politecn La Fe, Dept Gastroenterol, Valencia, Spain

[16] CIBEREHD, Valencia, Spain

[17] Hosp Univ Canarias, Dept Gastroenterol, San Cristobal la Laguna, Spain

[18] Hosp Univ Virgen del Rocio, Dept Gastroenterol, Seville, Spain

[19] Hosp HUA Alava, Dept Gastroenterol, Vitoria, Spain

[20] Hosp Univ Gran Canaria Dr Negrin, Dept Gastroenterol, Las Palmas Gran Canaria, Spain

[21] Hosp Gen Univ Ciudad Real, Dept Gastroenterol, Ciudad Real, Spain

[22] Hosp Gen Univ Dr Balmis, Dept Gastroenterol, Alicante, Spain

[23] CIBEREHD, Alicante, Spain

[24] Hosp Clin Valladolid, Dept Gastroenterol, Valladolid, Spain

[25] Hosp Univ Fuenlabrada, Dept Gastroenterol, Madrid, Spain

[26] Inst Invest Hosp Univ La Paz IdiPAZ, Madrid, Spain

[27] Hosp Univ Girona Dr Josep Trueta, Dept Gastroenterol, Girona, Spain

[28] Hosp Gen Univ Castellon, Dept Gastroenterol, Castellon de La Plana, Spain

[29] Hosp Gen San Jorge, Dept Gastroenterol, Huesca, Spain

[30] Hosp Univ Gregorio Maranon, Dept Gastroenterol, IiSGM, Madrid, Spain

[31] Univ Complutense Madrid, Madrid, Spain

[32] Hosp Univ Basurto, Dept Gastroenterol, Bilbao, Spain

[33] Hosp Univ Bellvitge, Dept Gastroenterol, Barcelona, Spain

[34] Hosp Univ Miguel Servet, Dept Gastroenterol, Zaragoza, Spain

[35] Hosp Univ Rio Hortega, Dept Gastroenterol, Valladolid, Spain

[36] Hosp Univ Parc Tauli, Dept Gastroenterol, Sabadell, Spain

[37] CIBEREHD, Barcelona, Spain

[38] Univ Pais Vasco UPV EHU, Biodonostia Hlth Res Inst, Hosp Univ Donostia, Dept Gastroenterol, Donostia San Sebastian, Spain

[39] CIBEREHD, Donostia San Sebastian, Spain

[40] Hosp Badalona Germans Trias & Pujol, Dept Gastroenterol, Badalona, Spain

[41] CIBEREHD, Badalona, Spain

[42] Inst Invest Sanitaria Aragon IIS Aragon, Hosp Clin Univ Lozano Blesa, Dept Gastroenterol, Zaragoza, Spain

[43] CIBEREHD, Zaragoza, Spain

[44] Hosp Univ Infanta Sofia, Dept Gastroenterol, Madrid, Spain

[45] Inst Invest Sanitaria BioBizkaia, Hosp Univ Galdakao, Dept Gastroenterol, Vizcaya, Spain

[46] Hosp Univ Henares, Dept Gastroenterol, Madrid, Spain

[47] Hosp Univ Burgos, Dept Gastroenterol, Burgos, Spain

[48] Parc Sanitari Sant Joan Deu, Dept Gastroenterol, Sant Boi De Llobregat, Spain

[49] Hosp Univ Nuestra Senora Candelaria, Dept Gastroenterol, Santa Cruz De Tenerife, CA, Spain

[50] Complexo Hosp Univ Pontevedra, Dept Gastroenterol, Pontevedra, Spain

来源：

DIGESTIVE AND LIVER DISEASE | 2024年 / 56卷 / 11期

关键词：

Ustekinumab; Vedolizumab; Complex perianal fistula; SUBCUTANEOUS USTEKINUMAB; MULTICENTER; EXPERIENCE; MANAGEMENT; INFLIXIMAB; EFFICACY;

D O I：

10.1016/j.dld.2024.05.009

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background: The efficacy of ustekinumab and vedolizumab for treating complex perianal fistula in Crohn's disease has been barely studied. We aimed to assess treatment persistence, clinical remission, and safety of these drugs in this context. Methods: Crohn's disease patients who had received ustekinumab or vedolizumab for the indication of active complex perianal fistula, were included. Clinical remission was defined according to Fistula Drainage Assessment Index (no drainage through the fistula upon gentle pressure) based on physicians' assessment. Results: Of 155 patients, 136 received ustekinumab, and 35 vedolizumab (16 received both). Median follow-up for ustekinumab was 27 months. Among those on ustekinumab, 54 % achieved remission, and within this group, 27 % relapsed during follow-up. The incidence rate of relapse was 11 % per patient-year. Multivariate analysis found no variables associated with treatment discontinuation or relapse. Median follow-up time for patients receiving vedolizumab was 19 months. Remission was achieved in 46 % of the patients receiving vedolizumab, and among them, 20 % relapsed during follow-up. The incidence rate of relapse was 7 % per patient-year. Adverse events were mild in 6 % on ustekinumab and 8 % on vedolizumab. Conclusion: Ustekinumab and vedolizumab appear effective, achieving remission in around half of complex perianal fistula patients, with favorable safety profiles. (c) 2024 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

引用

页码：1845 / 1853

页数：9

共 50 条

[41] Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naive patients with Crohn's disease: Results from the EVOLVE Expansion study
Ferrante, M.
Christensen, B.
Bressler, B.
Brett, N.
Bassel, M.
Kamble, P.
Adsul, S.
Gianchetti, L.
Scharl, M.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 116 - 117
[42] REAL-WORLD CLINICAL EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND USTEKINUMAB IN BIOLOGIC-NAIVE PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE EVOLVE EXPANSION STUDY
Ferrante, Marc
Christensen, Britt
Bressler, Brian
Brett, Neil R.
Bassel, Marielle
Kamble, Pravin
Adsul, Shashi
Gianchetti, Lauren
Scharl, Michael M.
GASTROENTEROLOGY, 2023, 164 (06) : S5 - S5
[43] Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients
Chapuis-Biron, Constance
Bourrier, Anne
Nachury, Maria
Nancey, Stephane
Bouhnik, Yoram
Serrero, Melanie
Armengol-Debeir, Laura
Buisson, Anthony
Tran-Minh, My-Linh
Zallot, Camille
Fumery, Mathurin
Bouguen, Guillaume
Abitbol, Vered
Viennot, Stephanie
Chanteloup, Elise
Rajca, Sylvie
Dib, Nina
Parmentier, Anne-Laure
Peyrin-Biroulet, Laurent
Vuitton, Lucine
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (07) : 719 - 727
[44] EFFECTIVENESS AND SAFETY OF SUBCUTANEOUS INFLIXIMAB IN PERIANAL CROHN'S DISEASE: A MULTICENTRE COHORT STUDY
Andre, Marie
Kirchgesner, Julien
Laharie, David
Guillo, Lucas
Abramowitz, Laurent
Nachury, Maria
Fumery, Mathurin
Amil, Morgane
Nancey, Stephane
Le Berre, Catherine
Moussata, Driffa
Buisson, Anthony
Fathallah, Nadia
Gilletta, Cyrielle
Uzzan, Mathieu
Duveau, Nicolas
Peyrin-Biroulet, Laurent
Nahon, Stephane
Savoye, Guillaume
Charkaoui, Maeva
Vicaut, Eric
Vuitton, Lucine
GASTROENTEROLOGY, 2024, 166 (05) : S280 - S281
[45] Effectiveness and safety of subcutaneous infliximab in perianal Crohn's disease: a multicentre cohort study
Andre, M.
Kirchgesner, J.
Laharie, D.
Guillo, L.
Abramowitz, L.
Seksik, P.
Nachury, M.
Fumery, M.
Amil, M.
Nancey, S.
Le Berre, C.
Moussata, D.
Buisson, A.
Fathallah, N.
Gilletta, C.
Uzzan, M.
Duveau, N.
Peyrin-Biroulet, L.
Nahon, S.
Savoye, G.
Charkaoui, M.
Vicaut, E.
Vuitton, L.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1577 - I1577
[46] Assessing the safety and effectiveness of 4 weekly Ustekinumab in Crohn's disease
Sewell, Charlotte
Cooney, Rachel
GUT, 2023, 72 (SUPPL_2) : A113 - A113
[47] Effectiveness, safety and persistence of treatment with ustekinumab in a cohort of patients with moderate-to-severe refractory Crohn's Disease
Morales Bermudez, A. I.
Bravo Aranda, A. M.
Martinez Burgos, M.
Olmedo Martin, R.
JOURNAL OF CROHNS & COLITIS, 2021, 15 : S509 - S510
[48] EFFECTIVENESS AND SAFETY OF USTEKINUMAB FOR CROHN'S DISEASE IN ROUTINE CLINICAL PRACTICE
Lynn, Amanda M.
Barsky, Maria
Ahmed, Waseem
Zullow, Samantha
Jairath, Vipul
Kochhar, Gursimran
Weiss, Aaron
Phipps, Meaghan
Agrawal, Mansi
Click, Benjamin H.
Meserve, Joseph
Swaminath, Arun
Bohm, Matthew
Sagi, Sashidhar
Fischer, Monika
Hudesman, David
Chang, Shannon
Lawlor, Garrett
Lukin, Dana J.
Ullman, Thomas A.
Boland, Brigid S.
Singh, Siddharth
Sandborn, William J.
Regueiro, Miguel D.
Shen, Bo
Kane, Sunanda V.
Loftus, Edward V.
Dulai, Parambir S.
GASTROENTEROLOGY, 2019, 156 (06) : S885 - S885
[49] Comparison of vedolizumab and ustekinumab treatment persistence in anti-TNF experienced Crohn's Disease patients
Eroglu, Z.
Yilmaz, V.
Er, R. E.
Soykan, I.
Toruner, M.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1182 - I1182
[50] REAL-WORLD CLINICAL EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND USTEKINUMAB IN BIOLOGIC-NAIVE PATIENTS WITH CROHN'S DISEASE BY DISEASE LOCATION: RESULTS FROM THE EVOLVE EXPANSION STUDY
Scharl, Michael M.
Christensen, Britt
Bressler, Brian
Brett, Neil R.
Gianchetti, Lauren
Kamble, Pravin
Adsul, Shashi
Farhat, Zeinab
Ferrante, Marc
GASTROENTEROLOGY, 2024, 166 (05) : S1422 - S1422

← 1 2 3 4 5 →